SeaCrest Wealth Management LLC grew its position in shares of Metlife Inc (NYSE:MET) by 16.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,058 shares of the financial services provider’s stock after buying an additional 1,441 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Metlife were worth $474,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in the business. Kavar Capital Partners LLC purchased a new position in shares of Metlife in the 2nd quarter valued at about $25,000. Meridian Wealth Management LLC purchased a new position in shares of Metlife in the 1st quarter valued at about $26,000. Motco increased its holdings in shares of Metlife by 160.6% in the 2nd quarter. Motco now owns 516 shares of the financial services provider’s stock valued at $26,000 after purchasing an additional 318 shares in the last quarter. Coastal Capital Group Inc. purchased a new position in shares of Metlife in the 2nd quarter valued at about $30,000. Finally, Meeder Asset Management Inc. increased its holdings in shares of Metlife by 2,474.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 798 shares of the financial services provider’s stock valued at $40,000 after purchasing an additional 767 shares in the last quarter. Institutional investors own 75.64% of the company’s stock.
MET has been the subject of a number of research analyst reports. ValuEngine downgraded shares of Metlife from a “hold” rating to a “sell” rating in a report on Thursday, August 1st. Morgan Stanley cut their price target on shares of Metlife from $54.00 to $53.00 and set an “equal weight” rating for the company in a report on Tuesday, August 20th. Citigroup cut their price target on shares of Metlife from $42.00 to $41.00 and set a “sell” rating for the company in a report on Friday, September 13th. Zacks Investment Research upgraded shares of Metlife from a “sell” rating to a “hold” rating and set a $51.00 price target for the company in a report on Friday, August 2nd. Finally, UBS Group increased their price objective on shares of Metlife from $46.00 to $47.00 and gave the company a “neutral” rating in a research note on Thursday, October 10th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $49.51.
Metlife (NYSE:MET) last issued its quarterly earnings data on Wednesday, July 31st. The financial services provider reported $1.38 EPS for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.07. The firm had revenue of $16.45 billion for the quarter, compared to analysts’ expectations of $16.43 billion. Metlife had a net margin of 9.28% and a return on equity of 9.75%. The firm’s revenue was down 22.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.30 EPS. As a group, research analysts expect that Metlife Inc will post 5.67 earnings per share for the current year.
MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.
Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metlife Inc (NYSE:MET).
Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.